Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Pa
- PDF / 467,325 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 71 Downloads / 211 Views
ORIGINAL COMMUNICATION
Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson’s disease Peter Hagell1 · Arja Höglund2 · Carina Hellqvist3 · Eva‑Lena Johansson4 · Berit Löwed4 · Anne‑Christine Sjöström5 · Carina Karlberg5 · Margareth Lundgren2 · Nil Dizdar6 · Anders Johansson2 · Thomas Willows2 · Johan Rådberg4 · Filip Bergquist5 Received: 4 May 2020 / Revised: 22 June 2020 / Accepted: 26 June 2020 © The Author(s) 2020
Abstract Continuous subcutaneous (s.c.) apomorphine infusion is an effective therapy for Parkinson’s disease (PD), but a limitation is the formation of troublesome s.c. nodules. Various chemically non-identical apomorphine formulations are available. Anecdotal experiences have suggested that shifting from one of these (Apo-Go PumpFill®; apoGPF) to another (Apomorphine PharmSwed®; apoPS) may influence the occurrence and severity of s.c. nodules. We, therefore, followed 15 people with advanced PD (median PD-duration, 15 years; median “off”-phase Hoehn and Yahr, IV) on apoGPF and with troublesome s.c. nodules who were switched to apoPS. Data were collected at baseline, at the time of switching, and at a median of 1, 2.5, and 7.3 months post-switch. Total nodule numbers (P
Data Loading...
